MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1021/acs.jproteome.2c00422

Медицинская библиотека · Journal of proteome research · 2024

Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19.

Michot Jean-Marie, Dozio Vito, Rohmer Julien, Pommeret Fanny, Roumier Mathilde, Yu Haochen, Sklodowki Kamil, Danlos François-Xavier, Ouali Kaissa, Kishazi Edina, Naigeon Marie, Griscelli Franck, Gachot Bertrand, Groh Matthieu, Bacciarello Giulia, Stoclin Annabelle, Willekens Christophe, Sakkal Madona, Bayle Arnaud, Zitvogel Laurence, Silvin Aymeric, Soria Jean-Charles, Barlesi Fabrice, Beeler Kristina, André Fabrice, Vasse Marc, Chaput Nathalie, Ackermann Felix, Escher Claudia, Marabelle Aurélien

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Circulating proteomes provide a snapshot of the physiological state of a human organism responding to pathogenic challenges and drug interventions. The outcomes of patients with COVID-19 and acute respiratory distress syndrome triggered by the SARS-CoV2 virus remain uncertain. Tocilizumab is an anti-interleukin-6 treatment that exerts encouraging clinical activity by controlling the cytokine storm and improving respiratory distress in patients with COVID-19. We investigate the biological determinants of therapeutic outcomes after tocilizumab treatment. Overall, 28 patients hospitalized due to severe COVID-19 who were treated with tocilizumab intravenously were included in this study. Sera were collected before and after tocilizumab, and the patient's outcome was evaluated until day 30 post-tocilizumab infusion for favorable therapeutic response to tocilizumab and mortality. Hyperreaction monitoring measurements by liquid chromatography-mass spectrometry-based proteomic analysis with data-independent acquisition quantified 510 proteins and 7019 peptides in the serum of patients. Alterations in the serum proteome reflect COVID-19 outcomes in patients treated with tocilizumab. Our results suggested that circulating proteins associated with the most significant prognostic impact belonged to the complement system, platelet degranulation, acute-phase proteins, and the Fc-epsilon receptor signaling pathway. Among these, upregulation of the complement system by activation of the classical pathway was associated with poor response to tocilizumab, and upregulation of Fc-epsilon receptor signaling was associated with lower mortality.

Для цитирования: Michot Jean-Marie, Dozio Vito, Rohmer Julien, Pommeret Fanny, Roumier Mathilde, Yu Haochen, Sklodowki Kamil, Danlos François-Xavier, Ouali Kaissa, Kishazi Edina, Naigeon Marie, Griscelli Franck, Gachot Bertrand, Groh Matthieu, Bacciarello Giulia, Stoclin Annabelle, Willekens Christophe, Sakkal Madona, Bayle Arnaud, Zitvogel Laurence, Silvin Aymeric, Soria Jean-Charles, Barlesi Fabrice, Beeler Kristina, André Fabrice, Vasse Marc, Chaput Nathalie, Ackermann Felix, Escher Claudia, Marabelle Aurélien. Circulating Proteins Associated with Anti-IL6 Receptor Therapeutic Resistance in the Sera of Patients with Severe COVID-19.. Journal of proteome research. 2024. DOI: 10.1021/acs.jproteome.2c00422.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.